Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + FOLFOXIRI + Bevacizumab in First-Line pMMR and Immunoscore IC-High Metastatic Colorectal Cancer
NCT06733038Phase 3Recruiting
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Nov 2024
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in colorectal cancer (CRC) (2 arms), sponsored by Gruppo Oncologico Nord Ovest. Primary endpoint: Progression Free Survival at 24 months. Started Nov 2024; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06733038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06733038.